1 research outputs found
Randomized trial of atopaxar in the treatment of patients with coronary artery disease:the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial
Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD